On April 17, 2019, Dong-A ST (Chairman Eom Dae-sig) announced the recruitment of Kim Young-seol, an endocrinology expert, as vice-president in a bid to achieve its vision of ‘leaping as a leading company with global new drugs’.

Vice-president Kim Young-seol is a doctor of medicine who has served as Dean of the College of Medicine, Kyunghee University and as Director of Kyunghee University Hospital, as well as an endocrinologist who has served as Chairman of the Korean Diabetes Association, Chairman of the Board of the Korean Endocrine Society, and Chairman of the Korean Society for the Study of Obesity.

He is expected to contribute to new drug development and strengthen the expertise of the medical business division by taking an advisory role in the development of new drugs in the endocrine area under development by Dong-A ST, developing and supporting the academic contents of Suganon, a diabetes treatment with a DPP-4 inhibitor mechanism, and taking charge of the symposium.

Dong-A ST is currently developing DA-1241, an anti-diabetes drug, and is working to transform the medical business division responsible for sales of ethical drugs into a service organization with an advanced capacity for delivering medical information.

An official of Dong-A ST said, “Dong-A ST is striving to establish a sustainable foundation for growth and to secure differentiated competitiveness in order to achieve its vision. We are looking ahead to improving our capacity to develop new drugs in the endocrine area and boosting the professionalism of our medical business division.”